HealthTree

Hur mår man med cancern efter ca ett år

Frailty’s Impact on Outcomes in Older MM Patients Treated with Bispecifics

Are Stem Cell Transplants Safe for Myelofibrosis Patients Over 70? | Muhammad Umair Mushtaq | #ASH24

Experiences With Teclistamab Side Effects?

Doug K.

Multiple Myeloma Discussion • December 19, 2024

Post-ASCT Strength & Balance: What To Expect?

Hi folks. I've relapsed 28 months after Carvykti and my doctor is suggesting teclistamab. I'd like to hear from those of you who have been on teclistamab. What is the real story on side effects? Thanks very much, Doug

HealthTree Research Results: Patient Experiences and Attitudes about Cannabis

Posted by

HealthTree

Read article

Epcoritamab as Single Therapy for Relapsed/Refractory CLL/SLL

Posted by

HealthTree

Epcoritamab as Single Therapy for Relapsed/Refractory CLL/SLL image

Read article

patrick

Multiple Myeloma Discussion • December 19, 2024

Dec 2024 Hi, folks; I'm a 68yo male, eight weeks post-autologous bone marrow transplant (ABMT) after a slumbering multiple myeloma (SMM) diagnosis in 2013, active multiple myeloma (MM) diagnosis in April 2024, radiation treatment of plasmacytoma and bone lesions in May/June; Zometa infusions through Aug to help with bone lesions. Velcade/Daratumamab/Revlamid/Dexamethasone in June/July/Aug; stem cell collection in Sept and transplant Oct 14. Five days later was hospitalized for gut infections, diverticulitis and typhlitis, for 8 days. Lots of diarrhea, some nausea but no vomiting, fatigue, peripheral neuropathy (showing up as occasional sharp pains, which wake me up a night, but mostly numbness of feet, inhibiting balance and movement) and loss of 25 pounds (about 13% of body mass), much of which seems to be muscle mass. Will likely restart Zometa for bones, daratumamab and revlamid for maintenance next month. Question: Have been improving slowly in movement/ leg strength/balance; thoughts on how much improvement I can expect?

Updates in Treatment Options for TP53-Mutant AML and MDS

A Unique BTK Inhibitor, Pirtobrutinib for Patients with Pretreated CLL | Jeff Sharman, MD | #ASH24

Duvelisib + Venetoclax: A Time-Limited, All Oral Option for CLL | Jennifer Crombie, MD | #ASH24

Promising Results for Odronextamab in Post CAR T Patients with DLBCL | Jennifer Crombie, MD | #ASH24

Analyzing the Impact of Smoking on Myelodysplastic Syndromes | Sangeeth Venugopal, MD | #ASH24

Adding Venetoclax to 7+3 Chemotherapy in Newly Diagnosed AML | Ioannis Mantzaris, MD | #ASH24

Understanding the ASH Research Collaborative- COSMIC Study | Saad Usmani, MD | #ASH24

Belantamab + Standard of Care for Newly Diagnosed Myeloma (DreaMM-9) | Saad Usmani, MD | #ASH24

Searching for a Bay Area SMM Support Group

Multiple Myeloma Discussion • December 18, 2024

SMM support group. I am located in the SFO bay area. I am trying to check if there is a local SMM group where people can share the info openly and collaboratively participate in various health related activities such as exercise, diet planning etc.

Studying Quality of Life With and Without Elotuzumab in Newly Diagnosed Myeloma

Social Determinants of Health Impact Myeloma FISH Testing | Amy Pierre, MSN, RN, ANP-BC | #ASH24

Dara-CyBorD vs CyBorD in Newly Diagnosed AL Amyloidosis| Hans Lee, MD | #ASH2024

Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024

Post-CAR-T Driving Restrictions after Week 4 In Myeloma Appear Unnecessary | Rahul Banerjee | #ASH24

24-hour Urine Testing Does Not Add Value to Myeloma Response Assessments | Rahul Banerjee | #ASH24

Plasmacytomas are More Genomically Complex than Myeloma in the Bone Marrow | Urvi Shah, MD | #ASH24

Daratumumab + Lenalidomide vs Lenalidomide Maintenance in Myeloma | Laahn Foster, MD | #ASH24